# RAIN (NCT03805841)

> Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

No report yet. It can be ordered.

- Drugs tested: tarloxotinib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03805841
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Rain Oncology Inc
- Conditions: NSCLC, Stage IV; NSCLC Stage IIIB; NSCLC, Stage IIIC; NSCLC, Recurrent; EGFR Exon 20 Insertion Mutation; HER2-activating Mutation; ERBB Fusion; NRG1 Fusion
- Interventions: tarloxotinib bromide
- Enrollment: 41
- Primary outcome: ORR

## Indexed commentary on RAIN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 6
- YouTube: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=rain-nct03805841

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03805841", "email": "<work email>"}; the inbox owner confirms by the emailed link.